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Background: Traditional assessment of patients with obstructive lung diseases (asthma and 
chronic obstructive pulmonary disease; COPD) relies on physiological tests. The COPD and 
Asthma Rotterdam Integrated Care Approach (CORONA) study aims to develop a diagnostic 
pathway with a more comprehensive approach to the assessment of patients with asthma and 
COPD in secondary care.
Methods: An eight-step method was used to develop and implement the pathway for patients 
with asthma or COPD referred to an outpatient hospital setting.
Results: The diagnostic pathway consists of an evidence-based set of measurements prioritized 
by a Delphi procedure. The pathway incorporates three innovative diagnostics: the metronome-
paced hyperventilation test to measure dynamic hyperinflation, an activity monitor to objectively 
evaluate physical activity in daily life, and the Nijmegen Clinical Screening Instrument as a 
comprehensive assessment tool to acquire detailed insight into symptoms, functional limita-
tions, and quality of life.
Conclusion: An innovative diagnostic pathway was developed and implemented for patients 
with obstructive lung diseases referred to secondary care. As this pathway aims to provide a 
comprehensive analysis of health status, it focuses on biomedical aspects and also reviews 
behavioral aspects that further elucidate the patient’s health status. The added value of the 
diagnostic pathway needs to be determined from both an organizational perspective and from 
the individual patient’s viewpoint.
Keywords: diagnostic pathway, integrated care, comprehensive assessment, shared decision-
making, health status
Introduction
Chronic obstructive pulmonary disease (COPD) is associated with a complex and 
heterogenic symptomatology, which includes pulmonary signs as dyspnea and cough, 
as well as general aspects such as fatigue, exercise limitation, and mood disturbances. 
However, airway obstruction is only partially responsible for these symptoms and only 
moderate correlations are found between airway obstruction and symptom severity. 
Partly independent of airway obstruction, other pulmonary function impairments like 
dynamic hyperinflation and disturbances in gas exchange might be present, adding to 
the symptom load.1 Moreover, extrapulmonary manifestations, such as peripheral muscle 
dysfunction and reduced physical activity, are important consequences of COPD and 
may add to symptom severity, exercise limitation, and reduced quality of life.2 Finally, 
illness perceptions and cognitions, self-management abilities, and adaptation to the 
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challenges of a chronic condition appear to be important 
moderators of the burden of disease in COPD.3
A similar line of reasoning applies to patients with 
bronchial asthma: both patients and physicians tend to under-
estimate severity, while multiple factors such as allergies, 
bronchial hyperactivity, adherence to medication, overweight, 
a low level of physical activity, functional deficits, and mood 
moderate the impact on the burden of disease.4
These different aspects of the burden of disease are rec-
ognized in the concept “health status”. Theoretical models 
and empirical studies defined health status as an overall 
concept, covering physiological functioning, symptoms, 
functional limitations, and quality of life as main domains.5 
These main domains are further subdivided into many more 
concrete conceptually distinct subdomains.6 In patients with 
COPD, a detailed overview of their health status by means 
of an integral assessment approach is essential for patient-
tailored treatment.6,7 This conceptualization of health status 
is very much in line with the concept “burden of disease” as 
it is defined in the Dutch Standards of Care for patients with 
asthma and COPD.8 This concept stresses the importance of 
the patient’s own experiences of the disease.9
In response to the complexity and heterogeneity of the 
impaired health status, it has been proposed to use a compre-
hensive, holistic approach to patients with obstructive lung 
disease9,10 and adopt a personal-goal-oriented patient care 
model.11 Although the international guidelines for asthma 
and COPD describe which aspects might be included in an 
integral assessment of health status in patients with asthma 
and COPD, they lack details on how to operationalize and 
deploy them.1,12 Some suggestions are provided for moni-
toring parameters, but are limited to the physical aspects 
of disease and do not address psychosocial and behavioral 
aspects.9,11
Therefore, the present study aims to design a structured 
diagnostic pathway for patients with asthma and COPD 
referred to secondary care. The objective is to make a 
comprehensive integral assessment of the health status and 
to identify behavioral aspects contributing to the impaired 
health status.8,13 This will guide the formulation of a person-
alized treatment plan for each patient, including pharmaco-
logical and nonpharmacological interventions. Moreover, 
the care pathway should be complementary and additional 
to the care provided in primary care.
Development of a diagnostic 
pathway
We used an eight-step method to develop, implement, evalu-
ate, and continuously monitor the diagnostic pathway for 
patients with asthma and COPD.14 This method describes a 
multidisciplinary approach, which aims to translate evidence-
based knowledge into clinical practice and was successfully 
applied in designing an evidence-based pathway for patients 
with a COPD exacerbation.14 Figure 1 presents the eight steps 
Figure 1 eight-step method used for development of the outpatient-based diagnostic pathway for patients with asthma and chronic obstructive pulmonary disease.
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adapted for our diagnostic pathway; each step is described 
separately in the following section.
Step 1: specification of the target 
population and composition of an expert 
team
The care population was specified as “all patients with 
asthma and COPD referred to the pulmonologist, either by 
their general practitioner or another medical specialist”. We 
choose a combined diagnostic pathway for both asthma and 
COPD because after the age of 40, distinguishing between 
asthma with chronic airflow limitation and COPD becomes 
problematic and many patients have features of both asthma 
and COPD.1,12 In addition, the process of unraveling behav-
ioral aspects that contributes to the impaired health status 
(an important aspect of our diagnostic pathway) is diagnosis 
independent and relevant for all patients with chronic disease. 
Another aspect is the economies of scale, ie, costs per patient 
reduce when using facilities for a larger target group.15
Delegates of health care professionals and of hospital 
management were included in the expert team to guarantee 
a broad support during the development and implementation 
process. This multidisciplinary team included a pulmonolo-
gist, physician assistant, specialist nurse, physical therapist, 
lung function technician, members of the respiratory manage-
ment unit, and a member of the administrative staff of the 
pulmonology department. The group was divided into two 
smaller teams: one responsible for the content of the diag-
nostic pathway and the second responsible for logistics.
An external group of experts from primary care (located 
within the referral area of the hospital) was assembled 
to address the embedding of this diagnostic assessment 
in primary care before referral and after discharge of the 
patient. Criteria for referral and discharge were defined in 
conjunction with the external group according to national 
guidelines. A template for referral to the diagnostic pathway 
was developed.
Step 2: identification and review of items 
essential for assessment
The starting point for the diagnostic pathway was the Dutch 
Standard of Care for patients with asthma and COPD. These 
standards are based on the international literature, which apply 
a model to understand the health status of a patient based on 
four domains: physiological impairment, symptoms, func-
tional impairment, and quality of life (including health-related 
quality of life).5,8,16 For each of these domains, we reviewed 
the available diagnostic tests, questionnaires, and severity 
indicators.17,18 We also reviewed which measurements were 
recommended in international and national guidelines for pri-
mary and secondary care.1,8,12,16 Furthermore, input was incor-
porated from the pulmonary rehabilitation literature in which 
a comprehensive assessment of the patient forms the basis of 
the management and selection of treatment modules.19
Step 3: national Delphi study
Although pulmonologists generally acknowledge the impor-
tance of the aforementioned domains, there is no consensus 
on which specific components should be part of an integral 
assessment in the diagnostics process in an outpatient pul-
monary department. Therefore, we performed a two-round 
Delphi process to identify the collective opinion.20 A nation-
wide panel of 153 stakeholders, recommended by their 
respective professional associations, was formed. The panel 
included pulmonologists, respiratory nurses, general practi-
tioners, advisors of health insurance companies, and delegates 
of patient organizations. Agreement between responders on 
the clinical importance of the various components of the 
diagnostic assessment was found in 29 of the 41 components 
(Table S1). Outcomes of the first round were used to develop 
the diagnostic pathway. The final results of the total Delphi 
process will be published more extensively elsewhere.
Step 4: final selection of components
The next step for the expert team was to develop a flowchart 
of activities required to assess the components that cover all 
four domains consistent with the Delphi round. The long list 
derived in Step 3 formed the basis for the final selection by 
the expert team. A justification for their selection is that this 
set should 1) reflect disease severity, 2) estimate the risk of 
future events, and 3) describe the impact of the disease on 
health status.
Step 5: detailed description of tools
The expert team selected specific tools to assess the afore-
mentioned components (subdomains) of the four main 
domains; these are systematically screened in every patient in 
the diagnostic trajectory. The tools that measure the compo-
nents in the integral assessment approach can be divided into 
diagnostic measurements that are discriminatory of specific 
pathologies or disease phenotypes, or tools that measure the 
impact of the disease.
Table 1 presents the selected tools to measure the four 
main domains and their subdomains.
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Physiological components in COPD and asthma
The most commonly encountered and modifiable risk factor 
that determines physiological dysfunction with accelerated 
decline of lung function is tobacco smoking.1,12 Exacerbations 
and comorbidities are registered in a structured way as both 
are important determinants of health status, as well as the 
prognosis of asthma and COPD.1,12,21 There is an association 
between a low body mass index (BMI) and poor prognosis 
in COPD and an association between a high BMI and poorer 
asthma control.22,23
Capillary blood gas values are obtained to evaluate pul-
monary gas exchange. Although PaO
2
 may be underestimated 
by this technique, levels of PaCO
2
 and oxygen saturation can 
be reliably measured.24
Spirometry and a flow–volume curve are obtained, using 
internationally accepted methods and references, to evaluate 
the presence and severity of airway obstruction and revers-
ibility. The forced expiratory volume in 1 second (FEV
1
) and 
its bronchodilator response indicates airflow obstruction and 
hyperresponsiveness. In COPD, severity of airflow obstruc-
tion is an independent risk factor for impaired health status 
and mortality.25
To evaluate the presence, severity, and reversibility of 
dynamic hyperinflation, the metronome-paced hyperventi-
lation (MPH) test is applied. Dynamic hyperinflation is an 
important measure of pulmonary impairment that affects 
symptoms and is easily measured with the MPH test.26 
Changes in lung volumes can occur without changes in FEV
1
 
and are more closely related to exercise performance than 
FEV
1
.26 Furthermore, hyperinflation is an important target 
for bronchodilator therapy.
In all patients aged .40 years, a chest X-ray is obtained 
to enable evaluation of relevant respiratory comorbidity and 
exclude alternative diagnoses.1,12
A radioallegrosorbent test (RAST) is performed in 
patients aged ,40 years or patients suspected of having 
asthma. The RAST is a radioimmunoassay test to detect 
specific IgE antibodies to known or suspected allergens to 
guide an allergic predisposition.12
Nitric oxide levels are measured in patients suspected 
of having asthma or aged ,40 years to assess the level of 
inflammation. This is a noninvasive, simple, and safe method 
to determine airway inflammation. A level of .50 ppb con-
firms the diagnosis of asthma.27
Symptoms associated with COPD and asthma
The most frequently reported symptom in COPD is breath-
lessness. The Medical Research Council (MRC) dyspnea 
questionnaire is a simple and standardized scale that mea-
sures functional disability due to breathlessness in patients 
with COPD.28
The Clinical COPD Questionnaire (CCQ) is developed to 
measure the health status in patients with COPD and consists 
of three separate domains: symptoms, functional state, and 
mental state. The Asthma Control Questionnaire (ACQ) 
measures the level of asthma control. These tools can be used 
to estimate disease severity, assess functional performance, 
and response to therapy.29,30
Table 1 Selected instruments and subdomains measured for 
each of the four domains of health status
COPD
1) Main domain physiological functioning
•	 history: eg, smoking habit, exacerbations, comorbidity
•	 BMI
•	 Capillary blood gases
•	 Spirometry and flow volume curve, reversibility
•	 Metronome-paced hyperventilation (MPh) test
•	 Chest X-ray (age .40 years)
2) Main domain symptoms
•	 Medical Research Council (MRC) dyspnea scale
•	 CCQ: subdomain symptoms
•	 NCSI: subdomain dyspnea and fatigue
3) Main domain functional limitations
•	 CCQ: subdomain functional state
•	 Dynaport triaxial accelerometer: actual activity level
•	 NCSI: subdomains subjective and behavioral impairment
4) Main domain quality of life
•	 CCQ: subdomain emotions
•	 NCSI: subdomains general quality of life, health-related quality of 
life, and satisfaction with relations
Asthma
1) Main domain physiological functioning
•	 history: eg, smoking habit, exacerbations, comorbidity
•	 BMI
•	 Capillary blood gases
•	 Spirometry and flow volume curve, reversibility
•	 Metronome-paced hyperventilation (MPh) test
•	 Chest X-ray
•	 Allergic assessment (RASt and blood eosinophils and total Ige)
•	 Nitric oxide (FeNO)
2) Main domain symptoms
•	 ACQ
•	 Medical Research Council (MRC) dyspnoea scale
•	 NCSI: subdomains dyspnea and fatigue
3) Main domain functional limitations
•	 ACQ
•	 Dynaport triaxial accelerometer: actual activity level
•	 NCSI: subdomains subjective and behavioral impairment
4) Main domain quality of life
•	 NCSI: subdomains general quality of life, health-related quality of 
life, and satisfaction with relations 
Abbreviations: RASt, radioallegrosorbent test; Ige, Immunoglobulin e; CCQ, 
Clinical COPD Questionnaire; NCSI, Nijmegen Clinical Screening Instrument; BMI, 
body mass index; ACQ, Asthma Control Questionnaire.
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To provide a valid, reliable, and more detailed descrip-
tion of general and disease-specific symptoms in patients 
with COPD and asthma, we selected the Nijmegen Clinical 
Screening Instrument (NCSI).3 The NCSI is an empirically 
composed battery of existing instruments providing a quick 
but highly detailed assessment of the main domains: symp-
toms (subdomains; dyspnea, fatigue, and dyspnea-related 
emotions), the main domain functional impairment (subdo-
mains: subjective and behavioral impairment), and the main 
domain quality of life (subdomains: general quality of life, 
health-related quality of life, and satisfaction with relation-
ships). For each subdomain normative data indicate “normal 
functioning”, “mild problems”, or “severe problems”.3 Thus 
the NCSI also provides information about a patient’s disease 
perception and shows the discrepancy between the severity 
of the physiological disorder on one hand and the severity 
of symptoms, functional impairment, and quality of life on 
the other. Results are presented graphically and an incorpo-
rated intervention (ie, discussing the graphical presentation 
of results in a semistructured way) helps formulate patient-
tailored treatment goals and increase the patient’s motivation 
to adopt adequate health behaviors and, thereby, activates 
adequate self-management.3
Functional limitations in COPD and asthma
The functional performance in COPD can easily be assessed 
with the functional status domain of the CCQ and with the 
subjective and behavioral impairment subdomains of the 
NCSI.6,29 To objectively measure physical activity over 
1 week, the Dynaport triaxial accelerometer was selected; this 
activity monitor assesses standardized and common physi-
cal activities in the range of intensity relevant to patients. 
Changes in walking speed and daily lying time are measured 
with a high level of accuracy.31
Quality of life in COPD and asthma
To measure quality of life in patients with COPD, the CCQ 
was selected.32,33 The NCSI has added value as it also mea-
sures general quality of life, health-related quality of life, 
and satisfaction with relations.30
Step 6: process flowchart: categorization 
of key measurements
Finally, the selected measurements were positioned in a 
diagnostic pathway that had to meet the following four 
requirements:
1) It had to comply with the principles of lean management; 
the pathway should enable a comprehensive analysis 
of the health status with the least possible diagnostic 
tests. It should optimize and not maximize integral 
assessment;
2) As disease severity in asthma and COPD changes over 
time, the pathway should facilitate “shared care” between 
primary and secondary care. Therefore, algorithms were 
developed to refer patients back to primary care if treat-
ment goals were reached, or to keep them in secondary 
care until predefined thresholds (as defined in the Dutch 
standard of Care) were reached;8,16
3) The diagnostic pathway aimed at optimizing integral 
assessment to improve self-management, patient satisfac-
tion, and adherence to treatment and health outcomes. 
This requires the active involvement of patients, for 
which we implemented personal goal setting using shared 
decision-making;
4) Finally, the set of measurements had to be feasible 
in a clinical setting for patients and for the hospital 
organization.
The basic diagnostic trajectory gives an in-depth view of the 
health status. However, in some patients additional assessment 
may be necessary, eg, additional pulmonary function testing, 
pulmonary imaging, or referral to another medical discipline. 
In addition, in patients with a low physical activity measured 
over 1 week, defined as steps/day ,5,000, a 6-minute walking 
test is added to measure the exercise capacity.2
Step 7: translation into strategies to 
monitor implementation
The diagnostic pathway was implemented for patients with 
asthma and COPD (Figure 2).
We developed two strategies to monitor implementa-
tion of the comprehensive assessment; (these data will be 
described elsewhere). In short: the first is an electronic clini-
cal chart review to check which measurements were actually 
performed. The results of this chart review are systematically 
recorded in the newly developed Integral Practice Analysis 
Tool (IPAT). Implementation will also be monitored using 
quantitative data from the hospital administrative system. 
Data will be extracted with regard to adherence to the pro-
gram by the team, the existing diagnostic variation between 
the pulmonologists, and the follow-up treatment in primary 
and secondary care.
Step 8: implementation and monitoring 
in a multidisciplinary team
The result, a 2-day stepped diagnostic pathway, includes a 
basic comprehensive health status assessment with a stepwise 
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Figure 2 Flowchart of the diagnostic pathway.
Abbreviations: ACQ, Asthma Control Questionnaire; gP, general practitioner; MRC, Medical Research Council; CCQ, Clinical COPD Questionnaire; 6-MWD, 6-minute 
walk distance; MM, move monitor; PAl, physical activity level.
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implementation in the respiratory outpatient department of a 
large teaching hospital (Sint Franciscus Gasthuis, Rotterdam, 
the Netherlands). Prior to implementation, each discipline 
(separately) received training in specific areas. The imple-
mentation occurred stepwise to allow any necessary adjust-
ments. The expert team discussed the logistics process on 
a monthly basis. In addition, every 6 weeks, the respiratory 
team evaluated the content of the assessment. All disciplines 
were requested to provide feedback on a regular basis; 
this resulted in some minor adjustments. The single most 
important change was the addition of an extra third visit after 
6 weeks; this is because, at 1 week, the diagnostic trajectory 
was too short to start specific therapeutic procedures that 
include behavioral change.
Discussion
A diagnostic pathway was designed to provide a comprehen-
sive overview of the patient’s health status to identify areas of 
behavioral improvement, and set personal targets for therapy 
based on shared decision-making. This innovative assessment 
schedule was successfully implemented in the daily routine 
care of a local outpatient pulmonary department.
International experts increasingly acknowledge the need 
and usefulness of an integrated care concept to improve the 
care for patients with obstructive pulmonary disease.9,10 How-
ever, international guidelines lack structured information on a 
diagnostic pathway for patients with more severe disease.1,12 
In the absence of guidelines, we developed the content of the 
diagnostic process for newly referred patients suspected to 
have obstructive lung disease that could be implemented in 
routine care in an outpatient pulmonary department.
Although the content of the diagnostic package seems to 
be relatively extensive, individual consequences of obstruc-
tive airway diseases are complex, show significant variation 
between patients, and cannot be reliably predicted from 
biomedical measurements such as FEV
1
. This was confirmed 
by the results of the Delphi procedure, the opinions of the 
experts, and the evidence-based therapeutic implications.
Three novel diagnostics were incorporated in the path-
way, ie, the MPH test to measure dynamic hyperinflation, an 
activity monitor to objectively evaluate physical activity in 
daily life, and the NCSI as a comprehensive assessment tool 
to gain detailed insight into symptoms, functional limitations, 
and quality of life.
Dynamic hyperinflation, but not airflow obstruction, is an 
increasingly important indicator of lung function impairment 
with clinical consequences for dyspnea, exercise capacity, 
and physical activity in COPD. Evidence-based therapeutic 
options are available to attenuate dynamic hyperinflation, 
including the use of a (long-acting) bronchodilator, exercise 
training, and breathing retraining.26
Physical inactivity is an extrapulmonary manifestation 
of obstructive lung disease and an important determinant of 
the burden of disease. A low physical activity should raise 
the question whether the patient is not willing to, or is not 
able to, exercise. The easiest way to assess physical activ-
ity is by use of a questionnaire. However, this may lead to 
significant over- or underestimation of physical activity. 
Reliable measures of physical activity can be obtained with 
activity monitors, like the Dynaport. This not only provides 
information on the number of steps/day, but also on the 
intensity of exercise, energy spent, and the time spent sitting 
or lying. All of these activities are known to be independent 
components of health and all can be a target for nonmedical 
intervention.
Successful adaptation to a chronic illness helps patients 
reduce their burden of disease and participate in social 
activities, despite existing physical limitations. Interventions, 
which correspond with this burden and focus on the patient 
needs, should support behavior change.34
In this respect, health-related quality of life questionnaires 
are essential to obtain comprehensive insight into the impact 
of the disease on a patient’s life. Therefore, we introduced our 
third innovative diagnostic tool: the NCSI. This tool captures 
all four domains (physiological functioning, symptoms, func-
tional impairment, and quality of life) by measuring multiple 
subdomains in a quick and detailed assessment. The results 
of this assessment are presented visually. It provides an in-
depth view of the implications of the disease for the patient 
and forms the starting point of a discussion on the patient’s 
role and personal goals, with subsequent treatment options 
to reach these goals.
This shared decision-making process results in a writ-
ten individual care plan to which patients and professionals 
feel committed and motivates the patient to start working 
on these goals.
Although we were successful in the development and 
implementation of an innovative diagnostic pathway for 
patients with obstructive lung disease, the added value still 
needs to be established.
The next step is to conduct a study on the effects of the 
introduction of the diagnostic pathway on the application of 
the principles of integrated care. In the longer term, if the 
diagnostic pathway is well implemented and collaboration 
with primary care is further established, the added value 
for outcomes relevant to patients needs to be proved by 
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a clinical study. Therefore, a necessary prerequisite is to 
develop and implement an effective intervention program in 
which interventions are offered to patients in line with the 
analysis of health status.
Conclusion
We succeeded in developing and implementing an innova-
tive diagnostic pathway for patients with obstructive lung 
disease referred to secondary care. As this diagnostic pathway 
aims to perform a comprehensive analysis of health status, it 
focuses not only on biomedical aspects of the disease but also 
reviews behavioral aspects that provide further information 
on the individual patient’s health status. Additional studies 
are required to determine the added value of the diagnostic 
pathway from an organizational perspective and from the 
individual patient’s viewpoint.
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Supplementary material
Table S1 Delphi consensus aspects
No Determinants Percentage
1 lung function 98.7
2 Comorbidities 97.5
3 Pulmonary medication 97.5
4 Respiratory complaints 97.5
5 Pulmonary history 96.3
6 hospital admission last year as a result of exacerbations 96.3
7 ICU admission last year as a result of exacerbations 95.0
8 Physical activity, subjective 95.0
9 exacerbation frequency last year 93.8
10 Airway obstruction and reversibility 93.8
11 Smoking status 92.5
12 Physical examination 91.5
13 Physical activity, objective 90.0
14 Nonpulmonary medication 88.8
15 Nutritional status 88.8
16 Allergic symptoms 88.8
17 Quality of life, objective 88.8
18 Allergy research (asthma) 87.5
19 Allergy, subjective 86.3
20 Lung volume (restriction, static hyperinflation) 86.3
21 Cardiac complaints 86.3
22 exposition 82.5
23 Classification of COPD in GOLD 81.3
24 Diffusion capacity 81.3
25 Anxiety and depression 81.3
26 exercise capacity 80.0
27 Quality of life, subjective 80.0
28 Dynamic hyperinflation 78.8
29 thorax X-ray 76.3
Notes: Of the 41 selected components for the diagnostic assessment, consensus was reached for 29 components. Consensus was reached when $75% of the respondents 
selected “(very) important” for a specific component rated on a seven-point Likert scale.
Abbreviations: ICU, intensive care unit; COPD, chronic obstructive pulmonary disease; gOlD, global initiative for chronic obstructive pulmonary disease.
